Paperonium

Cancer drugs · Clin Cancer Res · 2021

Summary: 11 of the 34 patients on both drugs responded. Its own table: 8.

The 34 patients on both drugsThe summary11 of 34 respondedIts own table8 of 34 responded
The 34 patients on both drugsThe summary11 of 34 respondedIts own table8 of 34 responded

Of the 34 patients on both drugs, the number who responded

The paper says

In the rising-dose stage of a trial of a new cancer drug, MK-4830, 84 patients took part: 50 got it alone, 34 together with an existing immune drug, pembrolizumab. The paper’s summary says 11 of those 34 responded: their tumors shrank by at least 30%.

Its own data show

Its own table counts 8 of the 34 as responding (24%), each with shrinkage that held on a second scan; one more whose shrinkage was not confirmed makes 9. The 11 is the paper’s count for all 84 patients: those 9, plus 1 on MK-4830 alone and 1 who later switched to both drugs.

A response rate is one group’s responders divided by that same group’s size. No group on both drugs in the paper has 11 responders. As a share of the 34, 11 makes the drug pair look better: about 32% instead of the table’s 24%. It is the summary’s only result on whether the treatment works.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors · Clin Cancer Res (2021) · doi:10.1158/1078-0432.CCR-21-2160